Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456979 | 1.00 | AHR (0.62) | AHRCYP3A4MEN1KMT2AIGF1R | |
| SCHEMBL3526160 | 0.86 | AHR (0.62) | AHRMEN1KMT2AFLT1ALDH1A1 | |
| SCHEMBL30787730 | 0.82 | AHR (0.53) | AHRCYP3A4MEN1KMT2AFLT1 | |
| SCHEMBL1751672 | 0.82 | AHR (0.53) | AHRCYP3A4MEN1KMT2AIGF1R | |
| SCHEMBL5302174 | 0.82 | AHR (0.53) | AHRCYP3A4MEN1KMT2AFLT1 | |
| SCHEMBL3073324 | 0.76 | MEN1 (0.47) | AHRCYP3A4MEN1KMT2AIGF1R | |
| SCHEMBL15613033 | 0.76 | CYP3A4 (0.37) | AHRCYP3A4MEN1KMT2AIGF1R | |
| SCHEMBL15893452 | 0.73 | GAA (0.52) | AHRCYP3A4MEN1KMT2AFLT1 | |
| SCHEMBL4133359 | 0.73 | CYP3A4 (0.38) | AHRCYP3A4MEN1KMT2AFLT1 | |
| SCHEMBL1702010 | 0.73 | AHR (0.47) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115641-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2024-06-06 | — | — | WO | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-9604964-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2925749-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-13 | — | — | US | disclosed |
| EP-2925749-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014078611-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-1999038865-A1 | 8-AZABICYCLO(3.2.1)OCT-2-ENE DERIVATIVES AS PESTICIDES | ZENECA LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | AHR 987/4885CYP3A4 520/4885MEN1 3518/4885 |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR65, GPR35 | AHR 415/4885CYP3A4 650/4885MEN1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.